A proposal hammered out by the EU, India, South Africa and the U.S. to allow IP waivers for COVID-19 vaccines is headed to all members of the World Trade Organization (WTO) for consideration.
For the first time since the early weeks of the COVID-19 pandemic in 2020, global deaths caused by the disease have fallen to their lowest point, as immunity against the SARS-CoV-2 virus and its variants continues to build. Infections and deaths appear to be decelerating, an optimistic sign that the pandemic may be nearing an end.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abeona, Adial, Asceneuron, Aura, Betta, Botanix, Brickell, Cero, Cognition, Eyepoint, Helsinn, Juniper, Nordic Nanovector, Spero.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Axsome, Biogen, Coherus, Horizon, Hutchmed, Ideaya, Junshi, Moderna, Myovant, Novavax, Regeneron, Sage, Supernus, Vaxxinity, Vertex, Vitti.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adverum, Aptorum, Kala, Milestone, Sorrento, Tarsus, Vertex, Zynerba.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bristol Myers Squibb, Finch, Gilead, Merck, Moderna, Pfizer.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Astrazeneca, Denali, First Wave, Galera, Innate, Lyra, Novo Nordisk, Rezolute, Roche, Stealth, Timber.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Astrazeneca, Beigene, Cara, CNS, Janssen, Jasper, Moderna, Mycovia, Nevakar, SQZ, Timber, Vifor, Xbiotech.
RSS
